Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 4

The Lancet Oncology

After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer compared with age-matched non-carrier controls. These findings support the use of targeted PSA screening in these men to identify those with clinically significant prostate cancer. Further annual screening rounds will need to confirm these findings.